Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant's Duet Stent Paces 34% Growth In Vascular Intervention Sales

This article was originally published in The Gray Sheet

Executive Summary

Guidant's Multi-Link Duet coronary stent garnered nearly half of the U.S. stent market in the third quarter of 1999, the company reported Oct. 14, pacing a 34% growth in the company's vascular intervention business to $290.1 mil.

You may also be interested in...

People Briefs: Owens & Minor, Laurimed, Xagenic, Intersect ENT

Owens & Minor launched a search to replace its retiring CEO; Laurimed named its new CEO; Xagenic hired a VP of product development; and Intersect ENT appointed a chief commercial officer.

Guidant, Medtronic AAA Grafts Approved By FDA; Guidant Begins Shipments

Guidant has begun shipping its Ancure endovascular graft for treatment of abdominal aortic aneurysm, and Medtronic is expected to launch its AneuRx AAA device shortly once the company's surgeon training program is finalized. FDA simultaneously approved the two devices on Sept. 28.

Abbott Facing FDA Consent Decree Over Alleged QSR Violations

Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts